Skip to main content

JDRF researchers reprogramme donor type 1 pancreas cells to produce insulin

In a project funded by JDRF, scientists have turned on a gene in cells from a person with type 1 diabetes that allows them to produce insulin again.
JDRF logo placeholder for author profile picture
Kate Lawton 29 July 2022

In a world-first, JDRF-funded Australian researchers have successfully turned an insulin gene back on by injecting a drug called GSK126 into pancreatic cells donated from one person with type 1 and two people without.

How do we make insulin?

Insulin is made by beta cells in the pancreas. Our bodies stop being able to make beta cells when we are babies whether we have type 1 diabetes or not. This is because the insulin gene that makes them gets turned off by a molecule called EZH2.

What is GSK126?

GSK126 is an existing drug that stops EZH2 from working, which enables the genes for producing insulin to start working again – essentially turning them back on. This allows other cells in the pancreas to develop into insulin-producing beta cells. GSK126 is currently licensed by the FDA – the organisation that approves drugs in the US – so we know it is safe for humans.

Why are beta cells so important?

When type 1 diabetes happens, the immune system attacks the beta cells, which means the body can’t produce its own insulin. The study’s lead researcher, Professor Sam El-Osta, said: “By the time someone is diagnosed with type 1 diabetes, much of their pancreatic beta cells have been totally destroyed by the immune system.” So, manipulating the insulin gene could allow people with type 1 to make their own beta cells again to replace those they have lost.

Our other beta cell research

You may be familiar with our research that aims to produce beta cells from stem cells, which are a type of cell that can transform into many other cell types. Although this research is exciting, we still have a little way to go before it is a viable treatment for people with type 1.

A future treatment for type 1 diabetes

So, how does this new drug compare to these beta cell therapies? Professor El-Osta said: “Our research shows vital insulin production after just two days of drug treatment when compared to three to four months with alternative approaches using stem cells. This non-surgical method has the added benefit that treatments are less vulnerable to the risks associated with transplants.”

A small study, so more research is needed

It’s important to remember that the study only used cells from three people, so much larger projects are needed to confirm their results. But Professor El-Osta, said: “The discovery of the genetic barrier to insulin which can be unlocked by a drug is an important milestone and a step in the right direction for the path to accelerate cures.”

Related news

Read more
Professor Richard Oram in the Research, Innovation, Learning and Development (RILD) building at the University of Exeter.
7 March 2024

New biochip launches that detects genetic risk of type 1 diabetes

A new test by Randox, developed with JDRF-funded researchers at the University of Exeter, is the first in the world to use genetics to quickly identify who is at high risk of developing type 1 diabetes.

Read more
A graphic of a DNA double helix with a piece being removed demonstrating genetic engineering.
Cure research
21 February 2024

Primate with type 1 diabetes becomes insulin-independent after receiving gene-edited cells without immunosuppression

A transplant of stem cells grown into pancreatic islets has allowed a primate with type 1 to make its own insulin again.

Read more
A small container containing three tablets of a novel glucose-responsive oral insulin.
29 January 2024

Early research shows glucose-responsive insulin tablets are safe and effective in animals

Researchers have developed a new oral insulin that travels in an inactive state to the liver and is only activated by rising blood glucose levels.

Read more
Researcher Safiya Naina Marikar pipetting in the lab.
Research
2 January 2024

Research breakthrough shows insulin-producing cells can be regenerated

We could be one step closer to replacing the need for regular insulin injections in people living with type 1 diabetes, thanks to JDRF-funded research in Australia published this week in the Nature journal.